Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy

Hyunjoon Kim, Lin Niu, Peter Larson, Tamara A. Kucaba, Katherine A. Murphy, Britnie R. James, David M Ferguson, Thomas S Griffith, Jayanth Panyam

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Cytotoxic T lymphocytes (CTLs) play a major role in cancer immunotherapy because of their ability to directly kill tumor cells and secrete tumor suppressive cytokines. Anticancer vaccines aim to provoke tumor-specific CTL responses, which require activation of antigen presenting cells (APCs) including dendritic cells (DCs) and macrophages. Therefore, a potent immunostimulatory adjuvant capable of activating APCs is an essential component of anticancer vaccines. In this study, we introduce novel TLR 7/8 bi-specific agonists that significantly enhance cytokine secretion compared to TLR7 mono-selective compounds. Encapsulation of these TLR 7/8 agonists in poly(lactide-co-glycolide) (PLGA) nanoparticles increased the co-stimulatory molecule expression and antigen presentation via MHC I by DCs compared to the soluble agonist. When administered subcutaneously, these nanoparticles migrated to draining lymph node and triggered DC activation and expansion. This lead to expansion of antigen-specific CD8 T cells and enhanced CTL response, which resulted in significant prophylactic and therapeutic efficacy in melanoma, bladder and renal cell carcinoma tumor models. Importantly, our studies demonstrate significant reductions in systemic metastasis with the nanoparticle vaccine. Our results suggest novel TLR 7/8 agonist-encapsulated nanoparticles are potent immunostimulatory adjuvants for cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)38-53
Number of pages16
JournalBiomaterials
Volume164
DOIs
StatePublished - May 1 2018

Fingerprint

T-cells
Immunotherapy
Nanoparticles
Vaccines
Tumors
Cytotoxic T-Lymphocytes
Antigens
Dendritic Cells
Neoplasms
Chemical activation
Cells
Antigen-Presenting Cells
Cytokines
Polyglactin 910
Macrophages
Encapsulation
CD8 Antigens
Antigen Presentation
Renal Cell Carcinoma
Molecules

Keywords

  • Cancer vaccine
  • Immunotherapy
  • Nanoparticle
  • TLR7/8 agonist

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

Cite this

Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. / Kim, Hyunjoon; Niu, Lin; Larson, Peter; Kucaba, Tamara A.; Murphy, Katherine A.; James, Britnie R.; Ferguson, David M; Griffith, Thomas S; Panyam, Jayanth.

In: Biomaterials, Vol. 164, 01.05.2018, p. 38-53.

Research output: Contribution to journalArticle

Kim, Hyunjoon ; Niu, Lin ; Larson, Peter ; Kucaba, Tamara A. ; Murphy, Katherine A. ; James, Britnie R. ; Ferguson, David M ; Griffith, Thomas S ; Panyam, Jayanth. / Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. In: Biomaterials. 2018 ; Vol. 164. pp. 38-53.
@article{64853760aae942a590b8bf12ed88b938,
title = "Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy",
abstract = "Cytotoxic T lymphocytes (CTLs) play a major role in cancer immunotherapy because of their ability to directly kill tumor cells and secrete tumor suppressive cytokines. Anticancer vaccines aim to provoke tumor-specific CTL responses, which require activation of antigen presenting cells (APCs) including dendritic cells (DCs) and macrophages. Therefore, a potent immunostimulatory adjuvant capable of activating APCs is an essential component of anticancer vaccines. In this study, we introduce novel TLR 7/8 bi-specific agonists that significantly enhance cytokine secretion compared to TLR7 mono-selective compounds. Encapsulation of these TLR 7/8 agonists in poly(lactide-co-glycolide) (PLGA) nanoparticles increased the co-stimulatory molecule expression and antigen presentation via MHC I by DCs compared to the soluble agonist. When administered subcutaneously, these nanoparticles migrated to draining lymph node and triggered DC activation and expansion. This lead to expansion of antigen-specific CD8 T cells and enhanced CTL response, which resulted in significant prophylactic and therapeutic efficacy in melanoma, bladder and renal cell carcinoma tumor models. Importantly, our studies demonstrate significant reductions in systemic metastasis with the nanoparticle vaccine. Our results suggest novel TLR 7/8 agonist-encapsulated nanoparticles are potent immunostimulatory adjuvants for cancer immunotherapy.",
keywords = "Cancer vaccine, Immunotherapy, Nanoparticle, TLR7/8 agonist",
author = "Hyunjoon Kim and Lin Niu and Peter Larson and Kucaba, {Tamara A.} and Murphy, {Katherine A.} and James, {Britnie R.} and Ferguson, {David M} and Griffith, {Thomas S} and Jayanth Panyam",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.biomaterials.2018.02.034",
language = "English (US)",
volume = "164",
pages = "38--53",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy

AU - Kim, Hyunjoon

AU - Niu, Lin

AU - Larson, Peter

AU - Kucaba, Tamara A.

AU - Murphy, Katherine A.

AU - James, Britnie R.

AU - Ferguson, David M

AU - Griffith, Thomas S

AU - Panyam, Jayanth

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Cytotoxic T lymphocytes (CTLs) play a major role in cancer immunotherapy because of their ability to directly kill tumor cells and secrete tumor suppressive cytokines. Anticancer vaccines aim to provoke tumor-specific CTL responses, which require activation of antigen presenting cells (APCs) including dendritic cells (DCs) and macrophages. Therefore, a potent immunostimulatory adjuvant capable of activating APCs is an essential component of anticancer vaccines. In this study, we introduce novel TLR 7/8 bi-specific agonists that significantly enhance cytokine secretion compared to TLR7 mono-selective compounds. Encapsulation of these TLR 7/8 agonists in poly(lactide-co-glycolide) (PLGA) nanoparticles increased the co-stimulatory molecule expression and antigen presentation via MHC I by DCs compared to the soluble agonist. When administered subcutaneously, these nanoparticles migrated to draining lymph node and triggered DC activation and expansion. This lead to expansion of antigen-specific CD8 T cells and enhanced CTL response, which resulted in significant prophylactic and therapeutic efficacy in melanoma, bladder and renal cell carcinoma tumor models. Importantly, our studies demonstrate significant reductions in systemic metastasis with the nanoparticle vaccine. Our results suggest novel TLR 7/8 agonist-encapsulated nanoparticles are potent immunostimulatory adjuvants for cancer immunotherapy.

AB - Cytotoxic T lymphocytes (CTLs) play a major role in cancer immunotherapy because of their ability to directly kill tumor cells and secrete tumor suppressive cytokines. Anticancer vaccines aim to provoke tumor-specific CTL responses, which require activation of antigen presenting cells (APCs) including dendritic cells (DCs) and macrophages. Therefore, a potent immunostimulatory adjuvant capable of activating APCs is an essential component of anticancer vaccines. In this study, we introduce novel TLR 7/8 bi-specific agonists that significantly enhance cytokine secretion compared to TLR7 mono-selective compounds. Encapsulation of these TLR 7/8 agonists in poly(lactide-co-glycolide) (PLGA) nanoparticles increased the co-stimulatory molecule expression and antigen presentation via MHC I by DCs compared to the soluble agonist. When administered subcutaneously, these nanoparticles migrated to draining lymph node and triggered DC activation and expansion. This lead to expansion of antigen-specific CD8 T cells and enhanced CTL response, which resulted in significant prophylactic and therapeutic efficacy in melanoma, bladder and renal cell carcinoma tumor models. Importantly, our studies demonstrate significant reductions in systemic metastasis with the nanoparticle vaccine. Our results suggest novel TLR 7/8 agonist-encapsulated nanoparticles are potent immunostimulatory adjuvants for cancer immunotherapy.

KW - Cancer vaccine

KW - Immunotherapy

KW - Nanoparticle

KW - TLR7/8 agonist

UR - http://www.scopus.com/inward/record.url?scp=85042427633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042427633&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2018.02.034

DO - 10.1016/j.biomaterials.2018.02.034

M3 - Article

C2 - 29482062

AN - SCOPUS:85042427633

VL - 164

SP - 38

EP - 53

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -